Pacific Clinical Research Management Group | Upland, CA

Research site

(Unclaimed)

Location

1317 W. Foothill Boulevard, Upland, California, United States of America

Site insights

Top conditions

Top treatments

Cariprazine

Centanafadine

BHV-7000

Psilocybin

Ubrogepant

GATE-251

ML-004

SEP-363856

Liafensine

Brexpiprazole

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 25 total trials

A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder

A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accept...

Enrolling

Generalized Anxiety Disorder

Drug: Placebo

Drug: SEP-363856

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. (3112 Ped BPD)

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United S...

Enrolling

Bipolar I Disorder

Depression

Drug: Placebo

Drug: Cariprazine

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

The primary purpose of this trial is to evaluate the safety and tolerability of centanafadine QD XR in pediatric subjects with ADHD.

Active, not recruiting

Attention Deficit/Hyperactivity Disorder

Drug: Centanafadine Hydrochloride

Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to...

Enrolling

Insomnia

Drug: Daridorexant 10 mg

Drug: Daridorexant 25 mg

Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Enrolling

Major Depressive Disorder

Drug: BHV-7000

Drug: Placebo

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Enrolling

Treatment Resistant Depression

Drug: Psilocybin

GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder

The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The mai...

Enrolling

Major Depressive Disorder

Drug: Zelquistinel

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Invitation-only

Migraine

Drug: Ubrogepant

Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Invitation-only

Major Depressive Disorder

Drug: BHV-7000

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18...

Enrolling

Acute Treatment of Migraine

Drug: Rimegepant (PF-07899801)

ML-004 in Adolescents and Adults with Autism Spectrum Disorders (ASD)

ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and ad...

Enrolling

Autism Spectrum Disorder

Drug: ML-004 Placebo

Drug: ML-004 (IR)/(ER) tablet

Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizop...

Active, not recruiting

Bipolar I Disorder

Schizophrenia

Drug: Cariprazine Flexible Dose

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in chil...

Enrolling

Pediatric Migraine

Drug: Rimegepant/BHV3000

Drug: Matching placebo

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) (Ubro Peds)

Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea...

Enrolling

Migraine

Drug: Placebo-Matching Ubrogepant

Drug: Ubrogepant